RU2009108147A - Иммуноглобулины - Google Patents
Иммуноглобулины Download PDFInfo
- Publication number
- RU2009108147A RU2009108147A RU2009108147/10A RU2009108147A RU2009108147A RU 2009108147 A RU2009108147 A RU 2009108147A RU 2009108147/10 A RU2009108147/10 A RU 2009108147/10A RU 2009108147 A RU2009108147 A RU 2009108147A RU 2009108147 A RU2009108147 A RU 2009108147A
- Authority
- RU
- Russia
- Prior art keywords
- hosm
- seq
- antibody
- interaction
- patient
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/248—IL-6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Microbiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
1. Антитело или антигенсвязывающий фрагмент, которые конкурентно ингибируют связывание гуманизированного терапевтического антитела, специфически связывающего онкостатин М человека (hOSM) и модулирующего взаимодействие между hOSM и gp130, содержащего тяжелую цепь с SEQ ID NO: 11 и легкую цепь с SEQ ID NO: 12, с OSM, в частности hOSM, более конкретно с сайтом II hOSM, в твердофазном иммуноферментном анализе (ELISA) при условии, что это конкурирующее антитело не содержит CDRH3 с SEQ ID NO: 42. ! 2. Фармацевтическая композиция, содержащая конкурирующее антитело по п.1. ! 3. Способ лечения пациента человека, страдающего заболеванием или расстройством, чувствительным к модуляции взаимодействия между hOSM и gp130 (таким как артритное заболевание, например ревматоидный артрит и/или остеоартрит), включающий стадию введения указанному пациенту терапевтически эффективного количества композиции по п.2.
Claims (3)
1. Антитело или антигенсвязывающий фрагмент, которые конкурентно ингибируют связывание гуманизированного терапевтического антитела, специфически связывающего онкостатин М человека (hOSM) и модулирующего взаимодействие между hOSM и gp130, содержащего тяжелую цепь с SEQ ID NO: 11 и легкую цепь с SEQ ID NO: 12, с OSM, в частности hOSM, более конкретно с сайтом II hOSM, в твердофазном иммуноферментном анализе (ELISA) при условии, что это конкурирующее антитело не содержит CDRH3 с SEQ ID NO: 42.
2. Фармацевтическая композиция, содержащая конкурирующее антитело по п.1.
3. Способ лечения пациента человека, страдающего заболеванием или расстройством, чувствительным к модуляции взаимодействия между hOSM и gp130 (таким как артритное заболевание, например ревматоидный артрит и/или остеоартрит), включающий стадию введения указанному пациенту терапевтически эффективного количества композиции по п.2.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0407193.2 | 2004-03-30 | ||
| GB0407197.3 | 2004-03-30 | ||
| GB0407197A GB0407197D0 (en) | 2004-03-30 | 2004-03-30 | Immunoglobulins |
| GB0407193A GB0407193D0 (en) | 2004-03-30 | 2004-03-30 | Immunoglobulins |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2006134477/10A Division RU2429245C2 (ru) | 2004-03-30 | 2005-03-29 | Иммуноглобулины |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2009108147A true RU2009108147A (ru) | 2010-09-20 |
Family
ID=35064447
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2006134477/10A RU2429245C2 (ru) | 2004-03-30 | 2005-03-29 | Иммуноглобулины |
| RU2009108147/10A RU2009108147A (ru) | 2004-03-30 | 2009-03-10 | Иммуноглобулины |
| RU2009108149/10A RU2009108149A (ru) | 2004-03-30 | 2009-03-10 | Иммуноглобулины |
| RU2009108148/10A RU2009108148A (ru) | 2004-03-30 | 2009-03-10 | Иммуноглобулины |
| RU2011121419/10A RU2011121419A (ru) | 2004-03-30 | 2011-05-30 | Иммуноглобулины |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2006134477/10A RU2429245C2 (ru) | 2004-03-30 | 2005-03-29 | Иммуноглобулины |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2009108149/10A RU2009108149A (ru) | 2004-03-30 | 2009-03-10 | Иммуноглобулины |
| RU2009108148/10A RU2009108148A (ru) | 2004-03-30 | 2009-03-10 | Иммуноглобулины |
| RU2011121419/10A RU2011121419A (ru) | 2004-03-30 | 2011-05-30 | Иммуноглобулины |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US7858753B2 (ru) |
| EP (2) | EP2404935A1 (ru) |
| JP (1) | JP4809828B2 (ru) |
| KR (1) | KR100942849B1 (ru) |
| AR (1) | AR048516A1 (ru) |
| AT (1) | ATE515515T1 (ru) |
| AU (1) | AU2005229457B2 (ru) |
| BR (1) | BRPI0509367A (ru) |
| CA (1) | CA2562953A1 (ru) |
| CY (1) | CY1112192T1 (ru) |
| DK (1) | DK1730191T3 (ru) |
| HK (1) | HK1103747A1 (ru) |
| HR (1) | HRP20110657T1 (ru) |
| IL (1) | IL178119A0 (ru) |
| MA (1) | MA28541B1 (ru) |
| NO (1) | NO20064886L (ru) |
| NZ (1) | NZ550225A (ru) |
| PE (1) | PE20060287A1 (ru) |
| PL (1) | PL1730191T3 (ru) |
| PT (1) | PT1730191E (ru) |
| RU (5) | RU2429245C2 (ru) |
| SG (1) | SG151292A1 (ru) |
| SI (1) | SI1730191T1 (ru) |
| TW (1) | TWI365746B (ru) |
| WO (1) | WO2005095457A2 (ru) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10303974A1 (de) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
| KR101667623B1 (ko) | 2005-11-30 | 2016-10-19 | 애브비 인코포레이티드 | 아밀로이드 베타 단백질에 대한 모노클로날 항체 및 이의 용도 |
| PL1954718T3 (pl) | 2005-11-30 | 2015-04-30 | Abbvie Inc | Przeciwciała skierowane przeciwko A globulomerowi, ich reszty wiążące antygeny, odpowiednie hybrydomy, kwasy nukleinowe, wektory, komórki gospodarze, sposoby wytwarzania tych przeciwciał, kompozycje zawierające te przeciwciała, zastosowania tych przeciwciał i sposoby stosowania tych przeciwciał |
| WO2007098547A1 (en) * | 2006-03-01 | 2007-09-07 | Apollo Life Sciences Limited | A molecule and chimeric molecules thereof |
| ES2514495T3 (es) * | 2006-05-25 | 2014-10-28 | Glaxo Group Limited | Anticuerpos humanizados modificados anti-interleucina-18 |
| US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
| EP2124952A2 (en) | 2007-02-27 | 2009-12-02 | Abbott GmbH & Co. KG | Method for the treatment of amyloidoses |
| EP2305300B1 (en) | 2008-07-10 | 2016-04-06 | Toray Industries, Inc. | Pharmaceutical composition for treatment and prevention of cancer |
| RU2498819C2 (ru) | 2008-08-05 | 2013-11-20 | Торэй Индастриз, Инк. | Фармацевтическая композиция для лечения и профилактики злокачественных опухолей |
| CA2735193A1 (en) * | 2008-08-26 | 2010-03-11 | Macrogenics, Inc. | T-cell receptor antibodies and methods of use thereof |
| US8309688B2 (en) * | 2008-12-30 | 2012-11-13 | Centocor Ortho Biotech Inc. | Monkey homolog of human oncostatin M and methods of use thereof |
| EP2258723A1 (en) * | 2009-06-02 | 2010-12-08 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Treatment of oncostatin M receptor ß mediated heart failure |
| AU2011211682B2 (en) | 2010-02-04 | 2015-08-13 | Toray Industries, Inc. | Pharmaceutical composition for treating and/or preventing cancer |
| MX342291B (es) | 2010-02-04 | 2016-09-23 | Toray Industries | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. |
| PT2532680E (pt) | 2010-02-04 | 2015-09-14 | Toray Industries | Composição medicinal para tratar e/ou prevenir o cancro |
| JP5742714B2 (ja) | 2010-02-04 | 2015-07-01 | 東レ株式会社 | 癌の治療及び／又は予防用医薬組成物 |
| PL2532743T3 (pl) | 2010-02-04 | 2015-09-30 | Toray Industries | Kompozycja farmaceutyczna do leczenia i/lub zapobiegania raka |
| MX336196B (es) | 2010-04-15 | 2016-01-11 | Abbvie Inc | Proteinas de union a amiloide beta. |
| MX358739B (es) | 2010-08-14 | 2018-09-03 | Abbvie Inc Star | Proteinas de union a amiloide beta. |
| EP2627356B1 (en) * | 2010-10-13 | 2019-05-22 | Janssen Biotech, Inc. | Human oncostatin m antibodies and methods of use |
| JP6351973B2 (ja) | 2010-11-23 | 2018-07-04 | グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ | 抗原結合タンパク質 |
| HUE039219T2 (hu) | 2011-08-04 | 2018-12-28 | Toray Industries | Gyógyászati készítmény rák kezelésére és/vagy megelõzésére |
| US9180188B2 (en) | 2011-08-04 | 2015-11-10 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prophylaxis of cancer |
| PT2740795T (pt) | 2011-08-04 | 2017-01-09 | Toray Industries | Composição de fármaco para o tratamento e/ou a prevenção de cancro |
| CA2865020C (en) | 2012-02-21 | 2021-01-26 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prevention of cancer |
| EP2818481B1 (en) | 2012-02-21 | 2019-08-07 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prevention of cancer |
| JP6187255B2 (ja) | 2012-02-21 | 2017-08-30 | 東レ株式会社 | 癌の治療及び／又は予防用医薬組成物 |
| KR102005786B1 (ko) | 2012-02-21 | 2019-07-31 | 도레이 카부시키가이샤 | 암의 치료 및/또는 예방용 의약 조성물 |
| BR112014023937A2 (pt) | 2012-03-30 | 2018-04-17 | Toray Industries | composição farmacêutica, agente farmacêutico de combinação e método de tratamento |
| PT2832366T (pt) | 2012-03-30 | 2018-01-25 | Toray Industries | Composição farmacêutica para o tratamento e/ou a prevenção de cancro de vesícula biliar |
| EA201592285A1 (ru) | 2013-05-30 | 2016-05-31 | Байоджен Ма Инк. | Антигенсвязывающие белки к рецептору онкостатина м |
| MX360671B (es) | 2013-08-09 | 2018-11-13 | Toray Industries | Composición farmacéutica para el tratamiento y/o prevención del cáncer. |
| US9550828B2 (en) | 2013-09-05 | 2017-01-24 | Boise State University | Oncostatin M (OSM) antagonists for preventing cancer metastasis and IL-6 related disorders |
| CN106459182B (zh) | 2013-12-30 | 2021-09-03 | 岸迈生物科技有限公司 | 串联fab免疫球蛋白及其用途 |
| ES2700149T3 (es) * | 2014-02-24 | 2019-02-14 | Takeda Gmbh | Proteínas de fusión de UTI |
| WO2016046738A1 (en) * | 2014-09-24 | 2016-03-31 | Università Degli Studi Di Padova | Composition to induce bone marrow stem cell mobilization |
| US20180024142A1 (en) * | 2015-01-29 | 2018-01-25 | Ares Trading S.A. | Immunoassays for high positively charged proteins |
| CA3011746A1 (en) | 2016-02-06 | 2017-08-10 | Epimab Biotherapeutics, Inc. | Fabs-in-tandem immunoglobulin and uses thereof |
| CA3018154A1 (en) | 2016-03-28 | 2017-10-05 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prevention of cancers |
| GB201614627D0 (en) * | 2016-08-30 | 2016-10-12 | Glaxosmithkline Ip Dev Ltd | Antigen binding proteins |
| FR3090637A1 (fr) * | 2018-12-21 | 2020-06-26 | Universite De Poitiers | Protéine de liaison spécifique capable de se lier spécifiquement à l’oncostatine M humaine (hOSM) et ses utilisations. |
| US11633457B2 (en) | 2019-04-11 | 2023-04-25 | Boise State University | Pharmaceutical compositions comprising oncostatin m (OSM) antagonist derivatives and methods of use |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DD266710A3 (de) | 1983-06-06 | 1989-04-12 | Ve Forschungszentrum Biotechnologie | Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase |
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| US4879231A (en) | 1984-10-30 | 1989-11-07 | Phillips Petroleum Company | Transformation of yeasts of the genus pichia |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| GB8610600D0 (en) | 1986-04-30 | 1986-06-04 | Novo Industri As | Transformation of trichoderma |
| WO1988007089A1 (en) | 1987-03-18 | 1988-09-22 | Medical Research Council | Altered antibodies |
| JP2919890B2 (ja) | 1988-11-11 | 1999-07-19 | メディカル リサーチ カウンスル | 単一ドメインリガンド、そのリガンドからなる受容体、その製造方法、ならびにそのリガンドおよび受容体の使用 |
| FR2646437B1 (fr) | 1989-04-28 | 1991-08-30 | Transgene Sa | Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant |
| US6291158B1 (en) | 1989-05-16 | 2001-09-18 | Scripps Research Institute | Method for tapping the immunological repertoire |
| EP0402226A1 (en) | 1989-06-06 | 1990-12-12 | Institut National De La Recherche Agronomique | Transformation vectors for yeast yarrowia |
| NZ243706A (en) | 1991-07-25 | 1994-08-26 | Idec Pharma Corp | Recombinant monkey antibodies, pharmaceutical compositions |
| WO1993006213A1 (en) | 1991-09-23 | 1993-04-01 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| GB9122820D0 (en) | 1991-10-28 | 1991-12-11 | Wellcome Found | Stabilised antibodies |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| GB9203459D0 (en) | 1992-02-19 | 1992-04-08 | Scotgen Ltd | Antibodies with germ-line variable regions |
| ATE149570T1 (de) | 1992-08-17 | 1997-03-15 | Genentech Inc | Bispezifische immunoadhesine |
| CA2163032C (en) | 1993-06-03 | 2001-02-06 | John Landon | Antibody fragments in therapy |
| JP3622208B2 (ja) | 1993-06-11 | 2005-02-23 | 東ソー株式会社 | 骨粗鬆症治療方法及び治療薬 |
| US5429746A (en) | 1994-02-22 | 1995-07-04 | Smith Kline Beecham Corporation | Antibody purification |
| US5739277A (en) | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
| GB9806530D0 (en) | 1998-03-26 | 1998-05-27 | Glaxo Group Ltd | Inflammatory mediator |
| ES2230848T3 (es) | 1998-04-28 | 2005-05-01 | Smithkline Beecham Corporation | Anticuerpos monoclonales con inmunogenicidad reducida. |
| EP2298809A3 (en) | 2001-07-12 | 2012-02-15 | FOOTE, Jefferson | Super humanized antibodies |
| GB0216648D0 (en) | 2002-07-18 | 2002-08-28 | Lonza Biologics Plc | Method of expressing recombinant protein in CHO cells |
-
2005
- 2005-03-29 KR KR1020067022671A patent/KR100942849B1/ko not_active IP Right Cessation
- 2005-03-29 PE PE2005000360A patent/PE20060287A1/es not_active Application Discontinuation
- 2005-03-29 SI SI200531371T patent/SI1730191T1/sl unknown
- 2005-03-29 DK DK05733043.3T patent/DK1730191T3/da active
- 2005-03-29 US US10/594,293 patent/US7858753B2/en not_active Expired - Fee Related
- 2005-03-29 SG SG200901959-7A patent/SG151292A1/en unknown
- 2005-03-29 RU RU2006134477/10A patent/RU2429245C2/ru not_active IP Right Cessation
- 2005-03-29 PT PT05733043T patent/PT1730191E/pt unknown
- 2005-03-29 AU AU2005229457A patent/AU2005229457B2/en not_active Ceased
- 2005-03-29 EP EP11167424A patent/EP2404935A1/en not_active Withdrawn
- 2005-03-29 WO PCT/GB2005/001147 patent/WO2005095457A2/en active Application Filing
- 2005-03-29 JP JP2007505621A patent/JP4809828B2/ja not_active Expired - Fee Related
- 2005-03-29 EP EP05733043A patent/EP1730191B1/en active Active
- 2005-03-29 CA CA002562953A patent/CA2562953A1/en not_active Abandoned
- 2005-03-29 BR BRPI0509367-8A patent/BRPI0509367A/pt not_active IP Right Cessation
- 2005-03-29 PL PL05733043T patent/PL1730191T3/pl unknown
- 2005-03-29 NZ NZ550225A patent/NZ550225A/en not_active IP Right Cessation
- 2005-03-29 AT AT05733043T patent/ATE515515T1/de active
- 2005-03-30 TW TW094110049A patent/TWI365746B/zh not_active IP Right Cessation
- 2005-03-30 AR ARP050101233A patent/AR048516A1/es unknown
-
2006
- 2006-09-14 IL IL178119A patent/IL178119A0/en unknown
- 2006-10-18 MA MA29397A patent/MA28541B1/fr unknown
- 2006-10-26 NO NO20064886A patent/NO20064886L/no not_active Application Discontinuation
-
2007
- 2007-06-12 HK HK07106321.0A patent/HK1103747A1/xx not_active IP Right Cessation
-
2009
- 2009-03-10 RU RU2009108147/10A patent/RU2009108147A/ru not_active Application Discontinuation
- 2009-03-10 RU RU2009108149/10A patent/RU2009108149A/ru not_active Application Discontinuation
- 2009-03-10 RU RU2009108148/10A patent/RU2009108148A/ru not_active Application Discontinuation
-
2010
- 2010-11-16 US US12/947,371 patent/US20110245470A1/en not_active Abandoned
-
2011
- 2011-05-30 RU RU2011121419/10A patent/RU2011121419A/ru not_active Application Discontinuation
- 2011-09-13 HR HR20110657T patent/HRP20110657T1/hr unknown
- 2011-09-29 CY CY20111100943T patent/CY1112192T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2009108147A (ru) | Иммуноглобулины | |
| RS52889B (sr) | Terapijsko humano anti-il-1r1 monoklonsko antitelo | |
| RU2421464C2 (ru) | Человеческие антитела к il-13 и их терапевтическое применение | |
| CY1119353T1 (el) | Θεραπευτικη χρηση αντισωματων anti-cs1 | |
| EA200970262A1 (ru) | Композиции и способы, относящиеся к антителам к глюкагоновым рецепторам | |
| RU2006115835A (ru) | Человеческие антитела против человеческого 4-1вв (cd137) | |
| RU2011144166A (ru) | Способы применения антител к il-22 человека | |
| NZ709390A (en) | Folate receptor 1 antibodies and immunoconjugates and uses thereof | |
| EE200700052A (et) | Antikeha he v?i mitme apo-lipoproteiin B fragmendi vastu | |
| IL200373A (en) | A monoclonal antibody that binds to 3erbb and a pharmacological preparation that includes the same to inhibit 3erbb signaling in humans | |
| EA201190132A1 (ru) | Гуманизированные антитела, связывающиеся с cd19, и их применение | |
| DK1684805T3 (da) | Anvendelse af antagonist anti-CD40-monoklonale antistoffer til behandling af multipel myeloma | |
| BRPI0821168B8 (pt) | anticorpo isolado que se liga ao il-21 humano, ou um fragmento deste, usos de dito anticorpo ou fragmento, e, hibridoma | |
| RS52782B (en) | HIGH AFINITY HUMAN ANTIBODIES FOR THE HUMAN IL-4 RECEPTOR | |
| PE20071055A1 (es) | Anticuerpos anti mn | |
| RU2011139083A (ru) | АНТИ-CεmX АНТИТЕЛА, СПОСОБНЫЕ СВЯЗЫВАТЬСЯ С mIgE ЧЕЛОВЕКА В ЛИМФОЦИТАХ | |
| ATE482722T1 (de) | Therapeutische verwendung von anti-cs1- antikörpern | |
| NZ594466A (en) | Human monoclonal antibodies to protein tyrosine kinase 7 (PTK7) and methods for using anti-PTK7 antibodies | |
| DE19207796T1 (de) | Antigen zur bindung von proteinen an proprotein-konvertase-subtilisin/kexin vom typ 9 (pcsk9) | |
| RS51829B (sr) | Ljudska antitela specifična za interleukin 15 (il-15) | |
| RU2011140509A (ru) | Гетеродимерные полипептиды il-17a/f и возможности их лечебного применения | |
| CY1110033T1 (el) | Τεχνητα ανθρωπινα θεραπευτικα αντισωματα εναντια σε ισομορφες cd45 | |
| UA96122C2 (ru) | Антитело или его антигенсвязующий фрагмент, которое специфически связывается с il-22ra, и его применение | |
| BR0207151A (pt) | Moléculas de aglutinação terapêuticas | |
| RU2011142183A (ru) | Средство для лечения ревматоидного артрита |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20130703 |